Outlook Therapeutics’ stock plummeted after the FDA rejected their application for a wet AMD drug. The rejection caused shares to drop by over 60%, leading to significant losses for investors. The company had been hopeful for approval, but the setback has raised concerns about the future of the drug’s development.

Read more at Investing.com: Outlook Therapeutics stock plunges after FDA rejects wet AMD drug application